Search clinical trials for: TMC278

Total 61 results

Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

Healthy

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

Hepatitis C | HIV

Belgium
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir

Hepatitis C Virus
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of California, San Francisco
National Cancer Institute (NCI)

Unknown

UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer

Kidney Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

UCN-01 in Treating Patients With Advanced Cancer

Lymphoma | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, China, Germany, South Africa, Russian Federation, Argentina, Brazil, Puerto Rico, Austria, Thailand, Mexico, Uganda
St Stephens Aids Trust

Completed

Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.

HIV Infection

United Kingdom
Janssen R&D Ireland

Completed

A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin

Healthy

Belgium
Janssen Infectious Diseases BVBA

Withdrawn

A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

Multi-drug Resistant Tuberculosis

China, Ukraine, Taiwan, Korea, Republic of, Peru, Brazil, Estonia, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey, Georgia, Mexico, Cambodia, Ethiopia
Janssen Pharmaceutical K.K.

Completed

A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants

Healthy

Japan
Tibotec Pharmaceuticals, Ireland

Terminated

TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.

HIV-1
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.

HIV | Hepatic Impairment | AIDS
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation

Pharmacokinetics | Bioavailability | HIV-1
Janssen Sciences Ireland UC

Active, not recruiting

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

Human Immunodeficiency Virus Type 1

Portugal, South Africa, Thailand, Uganda, Spain
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Janssen Research & Development, LLC

Completed

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

HIV

Italy, Thailand, Spain, Uganda, Portugal, South Africa
Tibotec BVBA

Completed

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

Tuberculosis
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278

HIV Infections
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.

HIV | Oral Contraceptive | AIDS
Janssen Infectious Diseases BVBA

Approved for marketing

Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis

Tuberculosis

Russian Federation, Lithuania
Janssen Research & Development, LLC

Active, not recruiting

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Healthy

United States, Netherlands
Tibotec BVBA

Completed

TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer

HIV | Tuberculosis
Tibotec Pharmaceuticals, Ireland
Raltegravir is provided by Merck.

Completed

TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir

HIV Infections
National Institute of Allergy and Infectious Diseases...
National Institute of Mental Health (NIMH)

Withdrawn

Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age

HIV Infections
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy

Leprosy, Multibacillary

Brazil
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.

HIV
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)

Pulmonary Tuberculosis

South Africa
Janssen Research & Development, LLC

Recruiting

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

Multidrug-Resistant Tuberculosis

Mozambique, Philippines, Russian Federation, South Africa, Uganda, Ukraine
Janssen Infectious Diseases BVBA

Completed

To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

Tuberculosis

China, Ukraine, Korea, Republic of, Peru, Estonia, Kenya, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey
Tibotec BVBA

Completed

A Study of TMC207 in Patients With Moderately Impaired Hepatic Function

Moderate Hepatic Impairment
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers

HIV Infections
National Cancer Institute (NCI)

Completed

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Taiwan Liposome Company

Completed

Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

Cancer

United States, Taiwan
Janssen Research & Development, LLC

Completed

A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants

Healthy

Belgium
Tibotec BVBA

Completed

TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions

Healthy Volunteer
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
Hamad Medical Corporation

Completed

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar (DOLCI)

Pneumonia | COVID | Coronavirus

Qatar
Janssen Infectious Diseases BVBA

Completed

TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Tuberculosis

South Africa, Peru, Latvia, Philippines, Russian Federation, Thailand, Brazil, India
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Tuberculosis, Multidrug-Resistant

Japan
Vanderbilt University

Completed

Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit (SMART-MED)

Critical Illness | Acute Kidney Injury

United States
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003)

Pulmonary Tuberculosis

South Africa
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers

HIV
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

HIV Infections | HIV-1

United States, France, United Kingdom, China, Belgium, Germany, Spain, Chile, Mexico, Portugal, Costa Rica, Panama, South Africa, Canada, Brazil, Puerto Rico, Russian Federation, Thailand, Australia, India
St Stephens Aids Trust

Terminated

Pre-Exposure Prophylaxis Using TMC278LA

HIV Infections

United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

HIV Infections | HIV-1 | Human Immunodeficiency Virus Type 1

United States, Australia, France, United Kingdom, Taiwan, Spain, Argentina, Portugal, Romania, South Africa, Canada, Denmark, Sweden, Netherlands, Brazil, Puerto Rico, Austria, Russian Federation, Thailand, Mexico
Global Alliance for TB Drug Development

Recruiting

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis

Drug Sensitive Tuberculosis | Pulmonary Tuberculosis | Pulmonary TB

Philippines, South Africa, Tanzania, Georgia, Uganda
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

Pulmonary Tuberculosis

South Africa
Tibotec BVBA

Completed

TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)

HIV Infections

South Africa

3

Subscribe